Minerva Neurosciences (NERV) director receives stock options for 50,000 shares

Rhea-AI Filing Summary

Minerva Neurosciences director David Kupfer received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $4.68 per share and expire on June 2, 2036. Following this award, he holds options for 50,000 shares directly.

The grant vests in four equal quarterly installments, with one-quarter vesting three months after June 3, 2026 and an additional quarter vesting every three months thereafter, subject to his continued service as a non-employee director on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kupfer David

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 50,000 options Exercise price: $4.68 per share Post-grant option holdings: 50,000 options +2 more

5 metrics

Options granted 50,000 options Stock Option (right to buy) covering common stock

Exercise price $4.68 per share Conversion/exercise price for granted options

Post-grant option holdings 50,000 options Total derivative shares following transaction

Option expiration June 2, 2036 Expiration date of granted stock options

Vesting structure 4 equal quarterly installments First quarter vests three months after June 3, 2026

Key Terms

Stock Option (right to buy), exercise price, vesting, non-employee director, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 4.6800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option vest in four equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

non-employee director financial

"subject in each case to the continued service of the Reporting Person as a non-employee director"

expiration date financial

"expiration_date: 2036-06-02T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kupfer David

(Last) (First) (Middle)

C/O MINERVA NEUROSCIENCES, INC.,

1500 DISTRICT AVENUE

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Minerva Neurosciences, Inc. [ NERV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.68	06/03/2026		A		50,000		(1)	06/02/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 3, 2026 and an additional 1/4 vesting every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.

	/s/ Frederick Ahlholm, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Minerva Neurosciences (NERV) director David Kupfer report in this Form 4?

David Kupfer reported receiving a grant of stock options for 50,000 Minerva Neurosciences shares. The options are a compensation award, giving him the right to buy common stock at a fixed exercise price if vesting and other conditions are met.

How many Minerva Neurosciences (NERV) shares are covered by Kupfer’s new stock options?

The grant covers options on 50,000 shares of Minerva Neurosciences common stock. These options increase his equity-linked exposure to the company, subject to vesting over time as he continues serving as a non-employee director on the board.

What is the exercise price of David Kupfer’s Minerva Neurosciences (NERV) stock options?

The options have an exercise price of $4.68 per share. This means Kupfer can purchase Minerva Neurosciences common stock at $4.68 for each option that vests and is exercised, if he chooses to do so before expiration.

When do David Kupfer’s Minerva Neurosciences (NERV) stock options expire?

The stock options expire on June 2, 2036. Kupfer must exercise any vested options before that expiration date; otherwise, the right to purchase those Minerva Neurosciences shares at the set exercise price will lapse.

How do the Minerva Neurosciences (NERV) stock options granted to Kupfer vest over time?

The 50,000 options vest in four equal quarterly installments. One-quarter vests three months after June 3, 2026, with an additional quarter vesting every three months thereafter, contingent on his continued service as a non-employee director.

Does this Minerva Neurosciences (NERV) Form 4 show Kupfer buying or selling shares on the market?

No, the Form 4 reports a grant of stock options as compensation, not an open-market trade. Kupfer acquired derivative rights to buy shares in the future; no market purchase or sale of common stock is disclosed here.